Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

141 results about "Adenocarcinoma of the lung" patented technology

Adenocarcinoma of the lung is the most common type of lung cancer, and like other forms of lung cancer, it is characterized by distinct cellular and molecular features. It is classified as one of several non-small cell lung cancers (NSCLC), to distinguish it from small cell lung cancer which has a different behavior and prognosis. Lung adenocarcinoma is further classified into several subtypes and variants. The signs and symptoms of this specific type of lung cancer are similar to other forms of lung cancer, and patients most commonly complain of persistent cough and shortness of breath. Adenocarcinoma is more common in patients with a history of cigarette smoking, and is the most common form of lung cancer in younger women and Asian populations. The pathophysiology of adenocarcinoma is complicated, but generally follows a histologic progression from cells found in healthy lungs to distinctly dysmorphic, or irregular, cells. There are several distinct molecular and genetic pathways that contribute to this progression. Like many lung cancers, adenocarcinoma of the lung is often advanced by the time of diagnosis. Once a lesion or tumor is identified with various imaging modalities, such as computed tomography (CT) or X-ray, a biopsy is required to confirm the diagnosis. Treatment of this lung cancer is based upon the specific subtype and the extent of spread from the primary tumor. Surgical resection, chemotherapy, radiotherapy, targeted therapy and immunotherapy are used in attempt to eradicate the cancerous cells based upon these factors.

Identification of early diagnosis markers of lung adenocarcinoma based on co-expression similarity, and constructing method of risk prediction model

ActiveCN109841281ARealize automatic classification predictionRealize non-invasive diagnosisHealth-index calculationMedical automated diagnosisCorrelation analysisUnsupervised clustering
The invention belongs to the technical field of lung adenocarcinoma prediction, and specifically relates to an identification of early diagnosis markers of lung adenocarcinoma based on co-expression similarity, and a constructing method of a risk prediction model. The constructing method includes the steps of: data remodeling and grouping, data standardization, phase specific gene extraction, geneco-expression correlation analysis, unsupervised cluster analysis, specific and non-specific co-expression network analysis, functional pathway gathering, significant variation pathway identification, screening of early screening marker genes by using an REE algorithm, establishment of a classification model based on early screening risk genes, survival analysis verification, and the like. The identification of early diagnosis markers of lung adenocarcinoma based on co-expression similarity, and the constructing method of a risk prediction model can realize the early diagnosis of lung cancer,and can identify gene markers which change significantly with the progress of lung cancer at the same time.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV

Fructus terminaliae billericae extract with anti-cancer effect, and preparation method of effective part of fructus terminaliae billericae extract

The invention relates an anticancer active part of fructus terminaliae billericae, and a preparation method of the anticancer active part. The invention comprises extraction of the part containing active components, study of a process for enriching by adopting macroporous absorption resin, identification of the active components in the active part, and use of the active part in in-vivo or in-vitroinhibition of liver cancer HepG2, lung cancer A549, lung adenocarcinoma NCI-H1703, gastric cancer BGC823, osteosarcoma cell MG-63, colorectal cancer HCT116, breast cancer MCF-7, neuroblastoma cells shsy5y, kidney cancer ACHN, normal liver cells L02, human breast ductal carcinoma cells ZR75-1, human colorectal adenocarcinoma cells Colo-205, human breast ductal carcinoma cells BT-474, human breastcancer cells T-47D, human cervical cancer cell line HeLa, liver cancer cells H22, and the like. The enrichment method applying the macroporous absorption resin to the anti-cancer active part of the fructus terminaliae billericae is simple in process, safe, non-toxic and low in production cost, and can be used for industrial production, thus having a great economic benefit and higher generalizationperformance.
Owner:BEIJING UNIV OF CHINESE MEDICINE

Method for cultivating lymph-node autologous CIK (cytokine-induced killer) cells and application of lymph-node autologous CIK cells

The invention belongs to the field of biotechnology and microbial animal cell lines and particularly relates to a method for cultivating lymph-node autologous CIK (cytokine-induced killer) cells and application of the lymph-node autologous CIK cells. The CIK cells are obtained by in-vitro cultivation of isolated lymph node tissue obtained in surgery in patients with lung cancer and are compared with the CIK cells obtained from cultivation of isolated peripheral blood, biological characteristics of the CIK cells and cytotoxicity effect on pulmonary granule cancer cells are observed, the result shows that the isolated lymph node issue of the surgical patients can be completely used for cultivation of CIK, in-vitro tumor-cytotoxicity cells are powerful in activity, and the activity and cancer inhibition function are prior to the CIK cells of the peripheral blood. The CIK cells can be used for preparing pulmonary granule and cancer inhibition products and made into compounds with chemotherapy drugs as well as used for adoptive immunity and intervention for postoperative patients with lung cancers, and occurrence rate for recurrence and metastasis of the postoperative patients with the lung cancers is beneficially decreased.
Owner:SHANGHAI CHEST HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products